Key facts
- Invirsa’s last known valuation is $38.0M (Nov 2023).
- It has raised $14.3M across 3 recorded rounds; the latest was Seed Round ($2.9M) in Jul 2025.
- Notable investors include Endless Frontier Labs, Jumpstart Ventures, JobsOhio Ventures, Rev1 Ventures, CincyTech — 8 tracked in total.
- Invirsa has filed 5 Form Ds with the SEC since 2020, most recently Aug 2025 ($2.9M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Invirsa
Funding rounds
3 roundsAbout Invirsa
Developer of a therapeutic platform designed to treat infectious and inflammatory eye diseases through activation of innate cellular defense and repair pathways. The company offers a novel approach demonstrating clinical efficacy in diabetic dry eye and infectious conjunctivitis, enabling patients with ocular surface disorders to experience improved healing and reduced disease burden.
- Sector
- Healthcare
- HQ
- Columbus, OH, United States
- Founded
- 2014
- Employees
- 8
- Website
- invirsa.com/
- Ownership
- Privately Held (backing)
Invirsa doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Invirsa shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Invirsa in its N-PORT filings yet. We sweep new filings monthly.